Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 trillion over the past year, according to GlobalData’s Pharma Intelligence Center Companies Database. billion for 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. trillion to $3.61 to $365.84.

Marketing 78

Marketing Biopharma Sales Pharma 78

MedCity News

JANUARY 11, 2024

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

Competition 108

Competition Sales Marketing Biopharma 108

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. How can we maximise marketing, sales, medical, access, and other teams’ efforts while making their jobs easier? Truly understanding the competitive landscape and market environment.

Competition 91

Competition Marketing Pharma Biopharma 91

The Marketing Advantage

MARCH 9, 2021

March 9, 2021 Critical to optimizing sales force productivity and efficiency is identifying the right HCP and/or account targets. However, in the complex pharma, biotech and medical device landscape, the easy way of targeting HCPs is, unfortunately, not the right way in most circumstances, and ultimately diminishes sales and adoption.

Sales 52

Sales Competition Marketing Biopharma 52

Pharmaceutical Technology

JUNE 29, 2022

Meanwhile, the pharma industry is undergoing somewhat of a transformation itself. According to Laursen, the decision to break into speciality enzymes was based on a look into the future of the biopharma market and an important assessment of how the company believes it can make a genuine difference.

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

pharmaphorum

JANUARY 27, 2023

While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines. There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.”

Pharma 52

Pharma Manufacturing Biopharma Medicine 52

Clarivate

MAY 14, 2024

With only two3 GLP-1 drugs currently approved for weight loss—Huadong Medicine’s version of daily dosed liraglutide and thrice-a-day dosed beinaglutide from Benamae Pharma—the gap is substantial and leaves a solid market opportunity for weight loss drugs. What’s leading to the boom in development of semaglutide biosimilars?

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). Under buy and bill (B&B) in Medicare Part B, physician practices profit from reimbursement (historically Average Sales Price + 6% before sequestration) as well as rebates and discounts negotiated with manufacturers for hitting volume levels.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52